News

Under the deal, both the firms have agreed to collaborate on the development of bacteriophage (or phage) based technology for a range of applications. Intralytix CEO John Woloszyn

Xeloda Tablets, 150mg and 500mg, USP are indicated as a treatment of metastatic breast and colorectal cancers. Pursuant to the agreement, the litigation was dismissed on 21 September

The agreement allows FKD to develop and commercialise Merck’s recombinant adenoviral interferon alfa 2b (rAd-IFN) to treat superficial bladder cancer. The agreement also includes an option to develop

Under the contract, the companies will use Vernalis’ fragment and structure-based drug discovery platform against LRRK2. As per the terms of the deal, Vernalis is entitled to receive

The agreement allows the companies to support for the planned clinical trials of a cancer drug – Kevetrin. Cellceutix develops drugs to treat preclinical cancer, anti-inflammatory and autism.

The company has already completed galeterone Phase 1 clinical trial for the treatment of patients with castration resistant prostate cancer (CRPC). The funding has been granted by Novartis

The trial aims to assess the impact of the drug on menstrual events, as well as liver function. In the trial, the patients will be administered with 12mg

TCN-032 was discovered utilizing Theraclone’s I-STAR platform. The trial aims to investigate the safety profile of a single intravenous administration of TCN-032 compared to placebo. The study expects

The company has also opened an additional study and recruiting patients at the Stanford University Medical Center in Palo Alto, CA. The study aims to investigate safety and